Federica Tavaglione

Title(s)Postdoctoral Scholar, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD). Hepatol Commun. 2025 Jun 01; 9(6). Díaz LA, Tavaglione F, Mittal N, Bettencourt R, Amangurbanova M, Johnson A, Marti-Aguado D, Tincopa M, Loomba R, Khan-Riches A, Madamba E, Siddiqi H, Richards L, Sirlin CB, Ajmera V, Loomba R. PMID: 40377491.
      View in: PubMed   Mentions:    Fields:    
    2. Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD. Aliment Pharmacol Ther. 2025 May 13. Zafer M, Tavaglione F, Romero-Gómez M, Loomba R. PMID: 40364529.
      View in: PubMed   Mentions:    Fields:    
    3. An Expert Consensus Delphi Panel in MetALD: Opportunities and Challenges in Clinical Practice. Clin Gastroenterol Hepatol. 2025 Apr 30. Diaz LA, Ajmera V, Arab JP, Huang DQ, Hsu C, Lee BP, Louvet A, Thiele M, Tavaglione F, Tincopa M, Pose E, Adams LA, Alazawi W, Arrese M, Bataller R, Duseja A, Liangpunsakul S, Lucey MR, Mathurin P, Mellinger J, Nakajima A, Ratziu V, Reau N, Rinella ME, Thursz M, Wong VW, Kamath PS, Loomba R. PMID: 40315973.
      View in: PubMed   Mentions:    Fields:    
    4. PNPLA3 I148M and Hepatocellular Carcinoma. Liver Int. 2025 Apr; 45(4):e70051. Tavaglione F, Pennisi G, Pelusi S. PMID: 40029157.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Letter on 'Head-To-Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study' Authors' Reply. Aliment Pharmacol Ther. 2025 Mar; 61(6):1084-1085. Tavaglione F, Loomba R. PMID: 39957604.
      View in: PubMed   Mentions:    Fields:    
    6. Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol-Authors' Reply. Aliment Pharmacol Ther. 2025 Mar; 61(6):1071-1072. Tavaglione F, Loomba R. PMID: 39954266.
      View in: PubMed   Mentions:    Fields:    
    7. Publisher Correction: Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2025 Feb; 31(2):700. Jamialahmadi O, De Vincentis A, Tavaglione F, Malvestiti F, Li-Gao R, Mancina RM, Alvarez M, Gelev K, Maurotti S, Vespasiani-Gentilucci U, Rosendaal FR, Kozlitina J, Pajukanta P, Pattou F, Valenti L, Romeo S. PMID: 39820106; PMCID: PMC11835728.
      View in: PubMed   Mentions:    Fields:    
    8. Design and rationale for a global novel non-invasive screening observational study using genetics and non-invasive methodologies to identify at-risk MASLD participants: The ALIGN study. Contemp Clin Trials Commun. 2025 Apr; 44:101437. Daniels SJ, Nelander K, Eriksson J, Jermutus L, Saillard J, Oyesola S, Tavaglione F, Arrese M, Ladrón de Guevara AL, Vespasiani-Gentilucci U, Alkhouri N, Blau JE. PMID: 39916681; PMCID: PMC11800087.
      View in: PubMed   Mentions:
    9. Head-to-Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study. Aliment Pharmacol Ther. 2025 Mar; 61(6):1043-1054. Tavaglione F, Amangurbanova M, Yang AH, Tincopa MA, Ajmera V, Richards L, Butcher C, Hernandez C, Madamba E, Singh S, Bettencourt R, Sirlin CB, Loomba R. PMID: 39825487; PMCID: PMC11870800.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    10. Machine Learning Reveals the Contribution of Lipoproteins to Liver Triglyceride Content and Inflammation. J Clin Endocrinol Metab. 2024 Dec 18; 110(1):218-227. Tavaglione F, Marafioti G, Romeo S, Jamialahmadi O. PMID: 38833012; PMCID: PMC11651681.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    11. Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024 Dec; 30(12):3624-3633. Raverdy V, Tavaglione F, Chatelain E, Lassailly G, De Vincentis A, Vespasiani-Gentilucci U, Qadri SF, Caiazzo R, Verkindt H, Saponaro C, Kerr-Conte J, Baud G, Marciniak C, Chetboun M, Oukhouya-Daoud N, Blanck S, Vandel J, Olsson L, Chakaroun R, Gnemmi V, Leteurtre E, Lefebvre P, Haas JT, Yki-Järvinen H, Francque S, Staels B, Le Roux CW, Tremaroli V, Mathurin P, Marot G, Romeo S, Pattou F. PMID: 39653777; PMCID: PMC11645276.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    12. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024 Dec; 30(12):3614-3623. Jamialahmadi O, De Vincentis A, Tavaglione F, Malvestiti F, Li-Gao R, Mancina RM, Alvarez M, Gelev K, Maurotti S, Vespasiani-Gentilucci U, Rosendaal FR, Kozlitina J, Pajukanta P, Pattou F, Valenti L, Romeo S. PMID: 39653778; PMCID: PMC11645285.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    13. Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA. Gut. 2024 Nov 11; 73(12):2045-2053. Yang AH, Tincopa MA, Tavaglione F, Ajmera VH, Richards LM, Amangurbanova M, Butcher C, Hernandez C, Madamba E, Singh S, Bettencourt R, Schnabl B, Sirlin CB, Loomba R. PMID: 39117370.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    14. Emerging Combination of Saroglitazar and Vitamin E for the Treatment of NAFLD and NASH. J Clin Exp Hepatol. 2024 Sep-Oct; 14(5):101449. Tavaglione F, Loomba R. PMID: 38881684; PMCID: PMC11170343.
      View in: PubMed   Mentions: 1  
    15. Poor accuracy and sustainability of the first-step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population. Aliment Pharmacol Ther. 2024 06; 59(11):1402-1412. De Vincentis A, Tavaglione F, Namba S, Kanai M, Okada Y, Kamatani Y, Maurotti S, Pedone C, Antonelli Incalzi R, Valenti L, Romeo S, Vespasiani-Gentilucci U. PMID: 38497224.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    16. Protein Phosphatase 1 Regulatory Subunit 3 Beta rs4240624 Genotype Is Associated With Gallstones and With Significant Changes in Bile Lipidome. Gastro Hep Adv. 2024; 3(5):594-601. Männistö VT, Kaminska D, Haal S, Asteljoki J, Luukkonen PK, Käkelä P, Tavaglione F, van Weeghel M, Neuvonen M, Niemi M, Romeo S, Nieuwdorp M, Pihlajamäki J, Groen AK. PMID: 39165418; PMCID: PMC11330930.
      View in: PubMed   Mentions:
    17. Non-invasive assessment of hepatic steatosis by ultrasound-derived fat fraction in individuals at high-risk for metabolic dysfunction-associated steatotic liver disease. Diabetes Metab Res Rev. 2024 Mar; 40(3):e3787. Tavaglione F, Flagiello V, Terracciani F, Gallo P, Capparelli E, Spiezia C, De Vincentis A, Palermo A, Scriccia S, Galati G, Napoli N, Daniels SJ, Blau JE, Carlsson B, Khazrai YM, Incalzi RA, Picardi A, Vespasiani-Gentilucci U. PMID: 38461408.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    18. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Res Sq. 2024 Feb 06. Romeo S, Jamialahmadi O, De Vincentis A, Tavaglione F, Malvestiti F, Li-Gao R, Mancina R, Alvarez M, Gelev K, Maurotti S, Vespasiani-Gentilucci U, Rosendaal F, Kozlitina J, Pajukanta P, Pattou F, Valenti L. PMID: 38405802; PMCID: PMC10889080.
      View in: PubMed   Mentions:
    19. IL32 downregulation lowers triglycerides and type I collagen in di-lineage human primary liver organoids. Cell Rep Med. 2024 01 16; 5(1):101352. Sasidharan K, Caddeo A, Jamialahmadi O, Noto FR, Tomasi M, Malvestiti F, Ciociola E, Tavaglione F, Mancina RM, Cherubini A, Bianco C, Mirarchi A, Männistö V, Pihlajamäki J, Kärjä V, Grimaudo S, Luukkonen PK, Qadri S, Yki-Järvinen H, Petta S, Manfrini S, Vespasiani-Gentilucci U, Bruni V, Valenti L, Romeo S. PMID: 38232700; PMCID: PMC10829727.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    20. Performance of non-invasive tests for liver fibrosis resolution after bariatric surgery. Metabolism. 2024 Apr; 153:155790. Raverdy V, Tavaglione F, Chatelain E, Caiazzo R, Saponaro C, Lassailly G, Verkindt H, Baud G, Marciniak C, Chetboun M, Oukhouya-Daoud N, Gnemmi V, Leteurtre E, Duhamel A, Philippe M, Marot G, Romeo S, Pattou F. PMID: 38219973.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    21. Predictors of controlled attenuation parameter in metabolic dysfunction. United European Gastroenterol J. 2024 04; 12(3):364-373. Bianco C, Pelusi S, Margarita S, Tavaglione F, Jamialahmadi O, Malvestiti F, Periti G, Rondena J, Tomasi M, Carpani R, Ronzoni L, Vidali M, Ceriotti F, Fraquelli M, Vespasiani-Gentilucci U, Romeo S, Prati D, Valenti L. PMID: 38141028; PMCID: PMC11017762.
      View in: PubMed   Mentions: 3  Translation:Humans
    22. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance. J Hepatol. 2023 12; 79(6):1524-1541. Hutchison AL, Tavaglione F, Romeo S, Charlton M. PMID: 37730124.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    23. Reply to: "Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank". Liver Int. 2023 06; 43(6):1362-1364. Tavaglione F, Jamialahmadi O, Ljungman C, Romeo S. PMID: 37166135.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Fatty liver disease genetic risk variants and interference on sex hormones. Liver Int. 2023 05; 43(5):958-961. Tavaglione F, Jamialahmadi O, Valenti L, Romeo S. PMID: 37161848.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    25. Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease. Liver Int. 2023 08; 43(8):1761-1771. Pipitone RM, Malvestiti F, Pennisi G, Jamialahmadi O, Dongiovanni P, Bertolazzi G, Pihlajamäki J, Yki-Järvinen H, Vespasiani-Gentilucci U, Tavaglione F, Maurotti S, Bianco C, Di Maria G, Enea M, Fracanzani AL, Kärjä V, Lupo G, Männistö V, Meroni M, Piciotti R, Qadri S, Zito R, Craxì A, Di Marco V, Cammà C, Tripodo C, Valenti L, Romeo S, Petta S, Grimaudo S. PMID: 37088979.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Fatty liver disease, heart rate and cardiac remodelling: Evidence from the UK Biobank. Liver Int. 2023 06; 43(6):1247-1255. Jamialahmadi O, Tavaglione F, Rawshani A, Ljungman C, Romeo S. PMID: 36883784.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    27. Effect of common genetic variants on the risk of cirrhosis in non-alcoholic fatty liver disease during 20 years of follow-up. Liver Int. 2022 12; 42(12):2769-2780. Holmer M, Ekstedt M, Nasr P, Zenlander R, Wester A, Tavaglione F, Romeo S, Kechagias S, Stål P, Hagström H. PMID: 36166317; PMCID: PMC9828463.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    28. Reply. Clin Gastroenterol Hepatol. 2023 03; 21(3):856-857. Tavaglione F, De Vincentis A, Jamialahmadi O, Vespasiani-Gentilucci U, Romeo S. PMID: 35835343.
      View in: PubMed   Mentions:    Fields:    
    29. Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2023 06; 21(6):1523-1532.e1. Tavaglione F, Jamialahmadi O, De Vincentis A, Qadri S, Mowlaei ME, Mancina RM, Ciociola E, Carotti S, Perrone G, Bruni V, Gallo IF, Tuccinardi D, Bianco C, Prati D, Manfrini S, Pozzilli P, Picardi A, Caricato M, Yki-Järvinen H, Valenti L, Vespasiani-Gentilucci U, Romeo S. PMID: 35421583.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    30. Rare ATG7 genetic variants predispose patients to severe fatty liver disease. J Hepatol. 2022 09; 77(3):596-606. Baselli GA, Jamialahmadi O, Pelusi S, Ciociola E, Malvestiti F, Saracino M, Santoro L, Cherubini A, Dongiovanni P, Maggioni M, Bianco C, Tavaglione F, Cespiati A, Mancina RM, D'Ambrosio R, Vaira V, Petta S, Miele L, Vespasiani-Gentilucci U, Federico A, Pihlajamaki J, Bugianesi E, Fracanzani AL, Reeves HL, Soardo G, Prati D, Romeo S, Valenti LV, EPIDEMIC Study Investigators. PMID: 35405176.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    31. A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2022 05; 6(5):1032-1044. Pennisi G, Pipitone RM, Enea M, De Vincentis A, Battaglia S, Di Marco V, Di Martino V, Spatola F, Tavaglione F, Vespasiani-Gentilucci U, Zito R, Romeo S, Cammà C, Craxì A, Grimaudo S, Petta S. PMID: 35146945; PMCID: PMC9035577.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    32. PSD3 downregulation confers protection against fatty liver disease. Nat Metab. 2022 01; 4(1):60-75. Mancina RM, Sasidharan K, Lindblom A, Wei Y, Ciociola E, Jamialahmadi O, Pingitore P, Andréasson AC, Pellegrini G, Baselli G, Männistö V, Pihlajamäki J, Kärjä V, Grimaudo S, Marini I, Maggioni M, Becattini B, Tavaglione F, Dix C, Castaldo M, Klein S, Perelis M, Pattou F, Thuillier D, Raverdy V, Dongiovanni P, Fracanzani AL, Stickel F, Hampe J, Buch S, Luukkonen PK, Prati D, Yki-Järvinen H, Petta S, Xing C, Schafmayer C, Aigner E, Datz C, Lee RG, Valenti L, Lindén D, Romeo S. PMID: 35102341; PMCID: PMC8803605.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    33. Reply. Clin Gastroenterol Hepatol. 2022 11; 20(11):2660-2661. De Vincentis A, Tavaglione F, Romeo S, Vespasiani-Gentilucci U. PMID: 35032632.
      View in: PubMed   Mentions:    Fields:    
    34. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery. Liver Int. 2022 02; 42(2):374-383. Tavaglione F, De Vincentis A, Bruni V, Gallo IF, Carotti S, Tuccinardi D, Spagnolo G, Ciociola E, Mancina RM, Jamialahmadi O, D'Alessio R, Bottazzi B, Manfrini S, Picardi A, Perrone G, Pozzilli P, Caricato M, Vespasiani-Gentilucci U, Romeo S. PMID: 34890093.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    35. Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. Int J Obes (Lond). 2022 03; 46(3):486-493. De Vincentis A, Tavaglione F, Spagnuolo R, Pujia R, Tuccinardi D, Mascianà G, Picardi A, Antonelli Incalzi R, Valenti L, Romeo S, Vespasiani-Gentilucci U. PMID: 34750514; PMCID: PMC8573310.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    36. Genetic risk scores and personalization of care in fatty liver disease. Curr Opin Pharmacol. 2021 12; 61:6-11. Bianco C, Tavaglione F, Romeo S, Valenti L. PMID: 34537584.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    37. A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores. Clin Gastroenterol Hepatol. 2022 03; 20(3):658-673. De Vincentis A, Tavaglione F, Jamialahmadi O, Picardi A, Antonelli Incalzi R, Valenti L, Romeo S, Vespasiani-Gentilucci U. PMID: 34091049.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    38. Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank. JHEP Rep. 2021 Jun; 3(3):100262. Tavaglione F, De Vincentis A, Jamialahmadi O, Pujia R, Spagnuolo R, Picardi A, Morano S, Valenti L, Romeo S, Vespasiani-Gentilucci U. PMID: 33997749; PMCID: PMC8099786.
      View in: PubMed   Mentions: 10  
    39. Understanding the underlying molecular pathways by which Mboat7/Lpiat1 depletion induces hepatic steatosis. J Lipid Res. 2021; 62:100047. Tavaglione F, Kono N, Romeo S. PMID: 33582144; PMCID: PMC7985689.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    40. Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. Gastroenterology. 2021 04; 160(5):1634-1646.e7. Jamialahmadi O, Mancina RM, Ciociola E, Tavaglione F, Luukkonen PK, Baselli G, Malvestiti F, Thuillier D, Raverdy V, Männistö V, Pipitone RM, Pennisi G, Prati D, Spagnuolo R, Petta S, Pihlajamäki J, Pattou F, Yki-Järvinen H, Valenti L, Romeo S. PMID: 33347879.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCells
    41. Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinol Diabetes Metab. 2020 Oct; 3(4):e00179. Tavaglione F, Targher G, Valenti L, Romeo S. PMID: 33102799; PMCID: PMC7576307.
      View in: PubMed   Mentions: 7     Fields:    
    42. Genetic variants in the MTHFR are not associated with fatty liver disease. Liver Int. 2020 08; 40(8):1934-1940. De Vincentis A, Mancina RM, Pihlajamäki J, Männistö V, Petta S, Dongiovanni P, Fracanzani AL, Valenti L, Tavaglione F, Romeo S, Vespasiani-Gentilucci U. PMID: 32460399.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    43. PCSK9 Inhibitors in a Statin-Intolerant Transgender Man With Heterozygous Familial Hypercholesterolemia: A Case Report. J Endocr Soc. 2019 Aug 01; 3(8):1461-1464. Pirazzi C, Tavaglione F, Tivesten Å, Romeo S. PMID: 31380502; PMCID: PMC6665951.
      View in: PubMed   Mentions:
    Federica's Networks
    Concepts (110)
    Derived automatically from this person's publications.
    _
    Co-Authors (13)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _